


## IN THE CLAIMS

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

1. (original) A compound of Formula A, or a pharmaceutically acceptable salt thereof:



wherein

R<sup>1</sup>, R<sup>12</sup>, and each R<sup>16</sup> are independently H, NR<sup>2</sup>R<sup>5</sup>, OR<sup>2</sup>, SR<sup>2</sup>, SOR<sup>2</sup>, SO<sub>2</sub>R<sup>2</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>5</sup>, OC(O)NR<sup>2</sup>R<sup>5</sup>, R<sup>11</sup>, C<sub>1-6</sub> alkyl, substituted alkyl, SR<sup>18</sup>; SO<sub>2</sub>R<sup>18</sup>; or N[SO<sub>2</sub>N(C<sub>1-6</sub> alkyl)<sub>2</sub>]R<sup>18</sup>; wherein substituted alkyl is C<sub>1-6</sub> alkyl substituted with O-C<sub>1-6</sub> alkyl, C<sub>3-8</sub> cycloalkyl, or aryl, wherein the cycloalkyl is optionally substituted with from 1 to 3 C<sub>1-6</sub> alkyl groups and the aryl is optionally substituted with from 1 to 5 substituents each of which is independently C<sub>1-6</sub> alkyl, O-C<sub>1-6</sub> alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, halo, CN, or NO<sub>2</sub>; with the proviso that no more than one of R<sup>1</sup>, R<sup>12</sup> and R<sup>16</sup> is other than H, C<sub>1-6</sub> alkyl, or substituted alkyl;

R<sup>2</sup> is

- 1) H, or
- 2) C<sub>1-6</sub> alkyl which is optionally substituted with aryl, C<sub>3-8</sub> cycloalkyl, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S;

R<sup>5</sup> is

- 1) H,
- 2) C<sub>1-6</sub> alkyl, optionally substituted at any carbon atom with halogen, aryl, SO<sub>2</sub>-C<sub>1-6</sub> alkyl, N(C<sub>1-6</sub> alkyl)<sub>2</sub>, or SO<sub>2</sub>NR<sup>u</sup>R<sup>v</sup>, wherein R<sup>u</sup> and R<sup>v</sup> are each independently a C<sub>1-6</sub> alkyl group or R<sup>u</sup> and R<sup>v</sup> together with the N to which they are attached form a 4- to 7-membered saturated heterocyclic ring containing at

least one carbon atom and from zero to 3 heteroatoms in addition to the N atom to which R<sup>u</sup> and R<sup>v</sup> are attached, wherein the additional heteroatoms are independently selected from N, O and S, and in which any ring S atom is optionally oxidized to SO or SO<sub>2</sub>, and wherein the heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently a C<sub>1-6</sub> alkyl group,

- 3) C(O)C<sub>1-6</sub> alkyl, where the alkyl is optionally substituted at any carbon atom with halogen, aryl, SO<sub>2</sub>-C<sub>1-6</sub> alkyl, N(C<sub>1-6</sub> alkyl)<sub>2</sub>, or SO<sub>2</sub>NR<sup>u\*</sup>R<sup>v\*</sup>, wherein R<sup>u\*</sup> and R<sup>v\*</sup> independently have the same definition as R<sup>u</sup> and R<sup>v</sup> respectively as set forth above,
- 4) C(O)-C<sub>1-6</sub> fluoroalkyl,
- 5) C(O)R<sup>7</sup>,
- 6) C(O)C(O)NR<sup>8</sup>R<sup>9</sup>,
- 7) SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>,
- 8) SO<sub>2</sub>C<sub>1-6</sub> alkyl, where the alkyl is optionally substituted at any carbon atom with halogen, aryl, SO<sub>2</sub>-C<sub>1-6</sub> alkyl or N(C<sub>1-6</sub> alkyl)<sub>2</sub>,
- 9) C(O)NR<sup>8</sup>R<sup>9</sup>,
- 10) SO<sub>2</sub>R<sup>7</sup>,
- 11) C(O)C(O)R<sup>10</sup>, where R<sup>10</sup> is a 4- to 7-membered saturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, and in which any ring S atom is optionally oxidized to SO or SO<sub>2</sub>, and wherein the heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently a C<sub>1-6</sub> alkyl group,
- 12) C(O)O-C<sub>1-6</sub> alkyl, or
- 13) SO<sub>2</sub>R<sup>20</sup>, wherein R<sup>20</sup> is a saturated heterocyclic ring independently having the same definition as R<sup>10</sup> set forth above;

or alternatively R<sup>2</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring containing at least one carbon atom and from zero to 3 heteroatoms in addition to the N atom to which R<sup>2</sup> and R<sup>5</sup> are attached, wherein the additional heteroatoms are independently selected from N, O and S, and in which any ring S atom is optionally oxidized to SO or SO<sub>2</sub>, and wherein the heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently a C<sub>1-6</sub> alkyl group;

R<sup>7</sup> and R<sup>11</sup> are each independently a 5- or 6-membered unsaturated heterocyclic ring or an unsaturated 9- or 10-membered heterobicyclic fused ring system, wherein the ring or bicyclic ring system contains from 1 to 4 heteroatoms independently selected from N, O and S, and in which any one or more of the N and S atoms is optionally oxidized, and wherein the ring is optionally substituted with from 1 to 3 substituents each of which is independently a C<sub>1-6</sub> alkyl group;

R<sup>8</sup> and R<sup>9</sup> are each independently selected from the group consisting of C<sub>1-6</sub> alkyl and aryl;

R<sup>14</sup>, R<sup>30</sup>, each R<sup>32</sup>, R<sup>34</sup> and R<sup>36</sup> are independently:

- (1) H,
- (2) C<sub>1-6</sub> alkyl, or
- (3) C<sub>1-6</sub> alkyl substituted with O-C<sub>1-6</sub> alkyl, C<sub>3-8</sub> cycloalkyl, or aryl,

wherein the cycloalkyl is optionally substituted with from 1 to 3 C<sub>1-6</sub> alkyl groups and the aryl is optionally substituted with from 1 to 5 substituents each of which is independently C<sub>1-6</sub> alkyl, O-C<sub>1-6</sub> alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, halo, CN, or NO<sub>2</sub>;

R<sup>18</sup> is C<sub>1-6</sub> alkyl substituted with C(O)NR<sup>W</sup>R<sup>X</sup>, wherein R<sup>W</sup> and R<sup>X</sup> are each independently a C<sub>1-6</sub> alkyl group or R<sup>W</sup> and R<sup>X</sup> together with the N to which they are attached form a 4- to 7-membered saturated heterocyclic ring containing at least one carbon atom and from zero to 3 heteroatoms in addition to the N atom to which R<sup>W</sup> and R<sup>X</sup> are attached, wherein the additional heteroatoms are independently selected from N, O and S, and wherein any of the ring S atoms is optionally oxidized to SO or SO<sub>2</sub>, and wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently a C<sub>1-6</sub> alkyl group;

R<sup>3</sup> is H or C<sub>1-6</sub> alkyl;

R<sup>4</sup> is

- 1) hydrogen,
- 2) C<sub>1-6</sub> alkyl which is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, OH, O-C<sub>1-6</sub> alkyl, O-C<sub>1-6</sub> haloalkyl, NO<sub>2</sub>, N(R<sup>a</sup>R<sup>b</sup>), C(O)R<sup>a</sup>, CO<sub>2</sub>R<sup>a</sup>, SR<sup>a</sup>, S(O)R<sup>a</sup>, SO<sub>2</sub>R<sup>a</sup>, or N(R<sup>a</sup>)CO<sub>2</sub>R<sup>b</sup>,
- 3) C<sub>1-6</sub> alkyl which is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is

optionally mono-substituted) each of which is independently halogen, OH, or O-C<sub>1-4</sub> alkyl, and which is substituted with 1 or 2 substituents each of which is independently:

- i) C<sub>3-8</sub> cycloalkyl,
  - ii) aryl,
  - iii) a fused bicyclic carbocycle consisting of a benzene ring fused to a C<sub>5-7</sub> cycloalkyl,
  - iv) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,
  - v) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or
  - vi) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic,
- 4) C<sub>2-5</sub> alkynyl optionally substituted with aryl,
  - 5) C<sub>3-8</sub> cycloalkyl optionally substituted with aryl,
  - 6) aryl,
  - 7) a fused bicyclic carbocycle consisting of a benzene ring fused to a C<sub>5-7</sub> cycloalkyl,
  - 8) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,
  - 9) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or
  - 10) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic;

wherein

each aryl in (3)(ii) or the aryl (4), (5) or (6) or each fused carbocycle in (3)(iii) or the fused carbocycle in (7) is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, OH, C<sub>1-6</sub> alkyl, -C<sub>1-6</sub> alkylene-OR<sup>a</sup>, C<sub>1-6</sub> haloalkyl, O-C<sub>1-6</sub> alkyl, O-C<sub>1-6</sub> haloalkyl, CN, NO<sub>2</sub>, N(R<sup>a</sup>R<sup>b</sup>), -C<sub>1-6</sub> alkylene-N(R<sup>a</sup>R<sup>b</sup>), C(O)N(R<sup>a</sup>R<sup>b</sup>), C(O)R<sup>a</sup>, CO<sub>2</sub>R<sup>a</sup>, -C<sub>1-6</sub> alkylene-CO<sub>2</sub>R<sup>a</sup>, OCO<sub>2</sub>R<sup>a</sup>, SR<sup>a</sup>, S(O)R<sup>a</sup>, SO<sub>2</sub>R<sup>a</sup>, N(R<sup>a</sup>)SO<sub>2</sub>R<sup>b</sup>, SO<sub>2</sub>N(R<sup>a</sup>R<sup>b</sup>), N(R<sup>a</sup>)C(O)R<sup>b</sup>, N(R<sup>a</sup>)CO<sub>2</sub>R<sup>b</sup>, -C<sub>1-6</sub> alkylene-N(R<sup>a</sup>)CO<sub>2</sub>R<sup>b</sup>, aryl, -C<sub>1-6</sub> alkylene-aryl, O-aryl, or -C<sub>0-6</sub> alkylene-HetA

wherein HetA is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, and the heteroaromatic ring is optionally fused with a benzene ring, and is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, O-C<sub>1-6</sub> alkyl, O-C<sub>1-6</sub> haloalkyl, oxo, or CO<sub>2</sub>R<sup>a</sup>;

each saturated heterocyclic ring in (3)(iv) or the saturated heterocyclic ring in (8) is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, O-C<sub>1-6</sub> alkyl, O-C<sub>1-6</sub> haloalkyl, oxo, aryl, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and


each heteroaromatic ring in (3)(v) or the heteroaromatic ring in (9) or each fused bicyclic heterocycle in (3)(vi) or the fused bicyclic heterocycle in (10) is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, O-C<sub>1-6</sub> alkyl, O-C<sub>1-6</sub> haloalkyl, oxo, aryl, or C<sub>1-6</sub> alkylene-aryl;

or alternatively R<sup>3</sup> and R<sup>4</sup> together with the nitrogen to which both are attached form a C<sub>3-7</sub> azacycloalkyl which is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently C<sub>1-6</sub> alkyl or oxo;

each R<sup>a</sup> and R<sup>b</sup> is independently hydrogen or C<sub>1-6</sub> alkyl; and

n is an integer equal to zero, 1, 2, or 3.

2. (original) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of Formula I:



wherein

R<sup>1</sup>, R<sup>12</sup>, and each R<sup>16</sup> are independently H, NR<sup>2</sup>R<sup>5</sup>, OR<sup>2</sup>, SR<sup>2</sup>, SOR<sup>2</sup>, SO<sub>2</sub>R<sup>2</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>5</sup>, OC(O)NR<sup>2</sup>R<sup>5</sup>, R<sup>11</sup>, C<sub>1-6</sub> alkyl, SR<sup>18</sup>, SO<sub>2</sub>R<sup>18</sup>, or N[SO<sub>2</sub>N(C<sub>1-6</sub> alkyl)<sub>2</sub>]R<sup>18</sup>; with the proviso that no more than one of R<sup>1</sup>, R<sup>12</sup>, and each R<sup>16</sup> is other than H or C<sub>1-6</sub> alkyl; and

R<sup>14</sup> is H or C<sub>1-6</sub> alkyl.

3. (original) A compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein:

R<sup>1</sup>, R<sup>12</sup>, and each R<sup>16</sup> are independently H, NR<sup>2</sup>R<sup>5</sup>, OR<sup>2</sup>, SR<sup>2</sup>, SOR<sup>2</sup>, SO<sub>2</sub>R<sup>2</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>5</sup>, OC(O)NR<sup>2</sup>R<sup>5</sup>, R<sup>11</sup>, CH<sub>3</sub>, SR<sup>18</sup>, SO<sub>2</sub>R<sup>18</sup>, or N[SO<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>]R<sup>18</sup>; with the proviso that no more than one of R<sup>1</sup>, R<sup>12</sup>, and R<sup>16</sup> is other than H or CH<sub>3</sub>;

R<sup>2</sup> is H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>-cyclopropyl, CH<sub>2</sub>-phenyl, CH(CH<sub>3</sub>)<sub>3</sub>-phenyl, or CH<sub>2</sub>-pyridinyl;

R<sup>5</sup> is

- 1) H,
- 2) C<sub>1-3</sub> alkyl, optionally substituted at any carbon atom with halogen, phenyl, SO<sub>2</sub>CH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, or SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>,
- 3) C(O)-C<sub>1-3</sub> alkyl, where the alkyl group is optionally substituted with halogen, phenyl, SO<sub>2</sub>CH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, or SO<sub>2</sub>NR<sup>u\*</sup>R<sup>v\*</sup> wherein R<sup>u\*</sup> and R<sup>v\*</sup> are either both CH<sub>3</sub> or together with the nitrogen atom to which they are attached form a saturated heterocyclic ring selected from the group consisting of azetidiny, pyrrolidiny, piperidiny, morpholiny, thiomorpholiny, imidazolidiny, oxazolidiny, isoxazolidiny, thiazolidiny, isothiazolidiny, thiazinany, thiadiazinany, and piperazinyl, wherein the saturated heterocyclic ring is

- optionally substituted with from 1 to 3 methyl groups, and wherein any ring S is optionally oxidized to SO or SO<sub>2</sub>,
- 4) C(O)CF<sub>3</sub>,
  - 5) C(O)R<sup>7</sup>,
  - 6) C(O)C(O)NR<sup>8</sup>R<sup>9</sup>,
  - 7) SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>,
  - 8) SO<sub>2</sub>-C<sub>1-3</sub> alkyl, where the alkyl is optionally substituted with halogen, phenyl, SO<sub>2</sub>CH<sub>3</sub> or N(CH<sub>3</sub>)<sub>2</sub>,
  - 9) C(O)NR<sup>8</sup>R<sup>9</sup>,
  - 10) SO<sub>2</sub>R<sup>7</sup>,
  - 11) C(O)C(O)R<sup>10</sup>, where R<sup>10</sup> is a saturated heterocyclic ring selected from the group consisting of azetidiny, pyrrolidiny, piperidiny, morpholiny, thiomorpholiny, imidazolidiny, oxazolidiny, isoxazolidiny, thiazolidiny, isothiazolidiny, thiazinany, thiadiazinany, and piperazinyl, wherein the saturated heterocyclic ring is attached to the rest of the compound via a ring nitrogen and is optionally substituted with from 1 to 3 methyl groups, and wherein any ring S is optionally oxidized to SO or SO<sub>2</sub>,
  - 12) C(O)OCH<sub>3</sub>, or
  - 13) SO<sub>2</sub>R<sup>20</sup>, wherein R<sup>20</sup> is a saturated heterocyclic ring independently having the same definition as R<sup>10</sup> set forth above;

or alternatively R<sup>2</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a saturated heterocyclic ring selected from the group consisting of azetidiny, pyrrolidiny, piperidiny, morpholiny, thiomorpholiny, imidazolidiny, oxazolidiny, isoxazolidiny, thiazolidiny, isothiazolidiny, thiazinany, thiadiazinany, and piperazinyl, wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 methyl groups, and wherein any ring S is optionally oxidized to SO or SO<sub>2</sub>;

R<sup>7</sup> and R<sup>11</sup> are each independently an unsaturated heterocycle selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, and triazolopyrimidinyl, in which any one of the N atoms is optionally oxidized and wherein the heterocycle is optionally substituted with from 1 to 3 substituents each of which is methyl;

R<sup>8</sup> and R<sup>9</sup> are independently selected from the group consisting of CH<sub>3</sub> and phenyl;

R<sup>14</sup> is H or CH<sub>3</sub>;


R<sup>18</sup> is CH<sub>2</sub>C(O)NR<sup>w</sup>R<sup>x</sup> wherein R<sup>w</sup> and R<sup>x</sup> are either both CH<sub>3</sub> or together with the nitrogen atom to which they are attached form a saturated heterocyclic ring selected from the group consisting of azetidiny, pyrrolidiny, piperidiny, morpholiny, thiomorpholiny, imidazolidiny, oxazolidiny, isoxazolidiny, thiazolidiny, isothiazolidiny, thiazinany, thiadiazinany, and piperazinyl, wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 methyl groups, and wherein any ring S is optionally oxidized to SO or SO<sub>2</sub>;

R<sup>3</sup> is hydrogen or CH<sub>3</sub>;

R<sup>4</sup> is C<sub>1-3</sub> alkyl substituted with an aryl selected from phenyl and naphthyl or with a heteroaryl selected from pyridiny, pyrimidiny, pyraziny, quinazolinyl, cinnoliny, quinoliny, and isoquinoliny, wherein the aryl or heteroaryl is optionally substituted with from 1 to 3 substituents each of which is independently halo, CH<sub>3</sub>, CF<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, or C(O)NH(CH<sub>3</sub>); and

n is an integer equal to zero, 1, 2, or 3.

4. (original) A compound according to claim 3, or a pharmaceutically acceptable salt thereof, which is a compound of Formula II:



wherein R<sup>1</sup> is H, NR<sup>2</sup>R<sup>5</sup>, OR<sup>2</sup>, SR<sup>2</sup>, SOR<sup>2</sup>, SO<sub>2</sub>R<sup>2</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>5</sup>, OC(O)NR<sup>2</sup>R<sup>5</sup>, R<sup>11</sup>, SR<sup>18</sup>, SO<sub>2</sub>R<sup>18</sup>, or N[SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>]SO<sub>2</sub>R<sup>18</sup>;

R<sup>5</sup> is

- 1) C<sub>1-3</sub> alkyl, optionally substituted at any carbon atom with halogen, phenyl, SO<sub>2</sub>CH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, or SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>,
- 2) C(O)-C<sub>1-3</sub> alkyl, where the alkyl group is optionally substituted with halogen, phenyl, SO<sub>2</sub>CH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, or SO<sub>2</sub>NR<sup>u\*</sup>R<sup>v\*</sup> wherein R<sup>u\*</sup> and R<sup>v\*</sup> are either both CH<sub>3</sub> or together with the nitrogen atom to which they are attached form a



saturated heterocyclic ring selected from the group consisting of azetidiny, pyrrolidiny, piperidiny, morpholiny, thiomorpholiny, imidazolidiny, oxazolidiny, isoxazolidiny, thiazolidiny, isothiazolidiny, thiazinany, thiadiazinany, and piperazinyl, wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 methyl groups, and wherein any ring S is optionally oxidized to SO or SO<sub>2</sub>,

- 3) C(O)CF<sub>3</sub>,
- 4) C(O)R<sup>7</sup>,
- 5) C(O)C(O)NR<sup>8</sup>R<sup>9</sup>,
- 6) SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>;
- 7) SO<sub>2</sub>-C<sub>1-3</sub> alkyl, where the alkyl is optionally substituted with halogen, phenyl, SO<sub>2</sub>CH<sub>3</sub> or N(CH<sub>3</sub>)<sub>2</sub>,
- 8) C(O)NR<sup>8</sup>R<sup>9</sup>,
- 9) SO<sub>2</sub>R<sup>7</sup>,
- 10) C(O)C(O)R<sup>10</sup>, where R<sup>10</sup> is a saturated heterocyclic ring selected from the group consisting of azetidiny, pyrrolidiny, piperidiny, morpholiny, thiomorpholiny, imidazolidiny, oxazolidiny, isoxazolidiny, thiazolidiny, isothiazolidiny, thiazinany, thiadiazinany, and piperazinyl, wherein the saturated heterocyclic ring is attached to the rest of the compound via a ring nitrogen and is optionally substituted with from 1 to 3 methyl groups, and wherein any ring S is optionally oxidized to SO or SO<sub>2</sub>,
- 11) C(O)OCH<sub>3</sub>, or
- 12) SO<sub>2</sub>R<sup>20</sup>, wherein R<sup>20</sup> is a saturated heterocyclic ring independently having the same definition as R<sup>10</sup> set forth above;

or alternatively R<sup>2</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a saturated heterocyclic ring selected from the group consisting of azetidiny, pyrrolidiny, piperidiny, morpholiny, thiomorpholiny, imidazolidiny, oxazolidiny, isoxazolidiny, thiazolidiny, isothiazolidiny, thiazinany, thiadiazinany, and piperazinyl, wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 methyl groups, and wherein any ring S is optionally oxidized to SO or SO<sub>2</sub>;


R<sup>12</sup> is H or CH<sub>3</sub>; and

R<sup>14</sup> is H or CH<sub>3</sub>.

5. (original) A compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein:

R<sup>3</sup> is hydrogen; and

R<sup>4</sup> is:



wherein X<sup>1</sup> and X<sup>2</sup> are each independently hydrogen, bromo, chloro, fluoro, CH<sub>3</sub>, CF<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, or C(O)NH(CH<sub>3</sub>); and Y<sup>1</sup> is hydrogen, bromo, chloro, fluoro, CH<sub>3</sub>, or CF<sub>3</sub>.


6. (original) A compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> is H, NR<sup>2</sup>R<sup>5</sup>, SCH<sub>2</sub>C(O)N(CH<sub>3</sub>)<sub>2</sub>, SO<sub>2</sub>CH<sub>2</sub>C(O)N(CH<sub>3</sub>)<sub>2</sub>, or N[SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>]CH<sub>2</sub>C(O)N(CH<sub>3</sub>)<sub>2</sub>;

R<sup>5</sup> is

- 1) CH<sub>3</sub>,
- 2) CH<sub>2</sub>-phenyl,
- 3) C(O)CH<sub>3</sub>,
- 4) C(O)CH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>,
- 5) C(O)CH<sub>2</sub>SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>,
- 6) C(O)C(CH<sub>3</sub>)<sub>2</sub>-SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>,
- 7) C(O)CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>,
- 8) C(O)CF<sub>3</sub>,
- 9) SO<sub>2</sub>CH<sub>3</sub>,
- 10) SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>,
- 11) C(O)C(O)N(CH<sub>3</sub>)<sub>2</sub>,
- 12) C(O)N(CH<sub>3</sub>)<sub>2</sub>,
- 13) SO<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>,
- 14) C(O)OCH<sub>3</sub>,


15) C(O)-T, wherein T is:




16) C(O)C(O)-N<chem>C1CCN1</chem>

17) C(O)CH<sub>2</sub>SO<sub>2</sub>-N<chem>C1CCOCC1</chem>


18) SO<sub>2</sub>-Q, wherein Q is:



19) SO<sub>2</sub>R<sup>20</sup>, wherein R<sup>20</sup> is:



or alternatively R<sup>2</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a saturated heterocyclic ring selected from the group consisting of



R<sup>4</sup> is:

- 1) p-fluorobenzyl,
- 2) 3-bromo-4-fluorobenzyl,
- 3) 3-chloro-4-fluorobenzyl,
- 4) 4-fluoro-3-methylbenzyl,
- 5) 3,4-difluorobenzyl,

- 6) 3-chlorobenzyl,
- 7) p-chlorobenzyl,
- 8) 3-chloro-4-methylbenzyl,
- 9) 3-methylbenzyl,
- 10) 4-fluoro-2[(methylamino)carbonyl]benzyl, or
- 11) quinolin-8-ylmethyl;

R<sup>12</sup> and R<sup>14</sup> are each independently H or CH<sub>3</sub>; and

n is an integer equal to zero, 1 or 2.


7. (original) A compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> is NR<sup>2</sup>R<sup>5</sup>;


R<sup>2</sup> is CH<sub>3</sub>;

R<sup>5</sup> is

- 1) C(O)CH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>,
- 2) C(O)C(O)N(CH<sub>3</sub>)<sub>2</sub>,
- 3) SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, or
- 4) SO<sub>2</sub>R<sup>20</sup>, wherein R<sup>20</sup> is:



or alternatively R<sup>2</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form




R<sup>4</sup> is:

- 1) p-fluorobenzyl,
- 2) 4-fluoro-3-methylbenzyl,
- 3) 3-chlorobenzyl, or
- 4) 3-chloro-4-methylbenzyl;

R<sup>12</sup> and R<sup>14</sup> are both H, except that when R<sup>5</sup> is C(O)C(O)N(CH<sub>3</sub>)<sub>2</sub> and R<sup>4</sup> is p-fluorobenzyl and n is 1, then R<sup>12</sup> and R<sup>14</sup> are either both H or both CH<sub>3</sub>; and

n is an integer equal to 1 or 2.

8. (original) A compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein


R<sup>5</sup> is C(O)C(O)N(CH<sub>3</sub>)<sub>2</sub>, or SO<sub>2</sub>R<sup>20</sup>, wherein R<sup>20</sup> is .

R<sup>4</sup> is p-fluorobenzyl or 4-fluoro-3-methylbenzyl;

R<sup>12</sup> and R<sup>14</sup> are both H, except that when R<sup>5</sup> is C(O)C(O)N(CH<sub>3</sub>)<sub>2</sub> and R<sup>4</sup> is p-fluorobenzyl and n is 1, then R<sup>12</sup> and R<sup>14</sup> are either both H or both CH<sub>3</sub>; and

n is an integer equal to 1 or 2.

9. (original) A compound according to claim 4, or a pharmaceutically acceptable salt thereof, which is a compound of Formula III:




wherein


R<sup>1</sup> is hydrogen, NR<sup>2</sup>R<sup>5</sup>, OR<sup>2</sup>, SR<sup>2</sup>, SOR<sup>2</sup>, SO<sub>2</sub>R<sup>2</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>5</sup>, or OC(O)NR<sup>2</sup>R<sup>5</sup>;

R<sup>3</sup> is hydrogen;




R<sup>4</sup> is




R<sup>2</sup> is

- 1) hydrogen,
- 2) CH<sub>3</sub>, or
- 3) CH(CH<sub>3</sub>)—; and

R<sup>5</sup> is

- 1) C(O)CH<sub>3</sub>,
- 2) C(O)CH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>,
- 3) CH<sub>3</sub>,
- 4) C(O)C(O)N(CH<sub>3</sub>)<sub>2</sub>,
- 5) SO<sub>2</sub>CH<sub>3</sub>,
- 6) SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>,
- 7) C(O)CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>,
- 8) SO<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>,
- 9) C(O)CF<sub>3</sub>,
- 10) ,
- 11) , or
- 12) CH<sub>2</sub>—;

or R<sup>2</sup> and R<sup>5</sup>, together with the nitrogen atom to which they are attached, form a heterocyclic ring selected from the group consisting of



10. (original) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-[acetyl(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(1-methyl-1H-imidazol-2-yl)carbonyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(methanesulfonyl)acetyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-[methyl(pyrazin-2-ylcarbonyl)amino]-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-[benzyl(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-morpholin-4-yl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-4-oxo-9-piperidin-1-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-(dimethylamino)-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-4-oxo-9-pyrrolidin-1-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N1-(2-([(4-fluorobenzyl)amino]carbonyl))-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N1,N2,N2-trimethylethanediamide;

N-(4-fluorobenzyl)-3-hydroxy-9-[methyl(methanesulfonyl)amino]-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-([(dimethylamino)sulfonyl](methyl)amino)-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-{[(methanesulfonyl)acetyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-[(N,N-dimethylglycyl)(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-(methyl{[(methanesulfonyl)methyl]sulfonyl}amino)-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(+)-9-([(dimethylamino)sulfonyl](methyl)amino)-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-9-([(dimethylamino)sulfonyl](methyl)amino)-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-N1-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N1,N2,N2-trimethylethanediamide;

(+)-N1-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N1,N2,N2-trimethylethanediamide;

(+)-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-9-[[[(1S)-1-phenylethyl](trifluoroacetyl)-amino]-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-9-[[[(1S)-1-phenylethyl](trifluoroacetyl)-amino]-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-2-carboxamide;

N-(3-bromo-4-fluorobenzyl)-9-[[[(dimethylamino)sulfonyl](methyl)amino]-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-[[[(dimethylamino)sulfonyl]acetyl](methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-{ethyl[(methylsulfonyl)acetyl]amino}-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-(1,1-dioxido-1,2-thiazinan-2-yl)-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(3,4-difluorobenzyl)-3-hydroxy-9-{methyl[(methylsulfonyl)acetyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-[[[(dimethylamino)sulfonyl](ethyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(+)-N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(methylsulfonyl)acetyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;



(-)-N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(methylsulfonyl)acetyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanedi-  
amide;

N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanedi-  
amide;

N-(2-{[(3-chlorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanedi-  
amide;

N-(4-fluorobenzyl)-3-hydroxy-9-(6-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl)-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanedi-  
amide;

(-)-N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanedi-  
amide;

(+)-N-(4-fluorobenzyl)-3-hydroxy-9-(6-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl)-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-[methyl(pyrrolidin-1-ylsulfonyl)amino]-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-[(azetidin-1-ylsulfonyl)(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-N-(4-fluorobenzyl)-3-hydroxy-9-[methyl(morpholin-4-ylsulfonyl)amino]-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(+)-N-(4-fluorobenzyl)-3-hydroxy-9-[methyl(morpholin-4-ylsulfonyl)amino]-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(2-{[(3-bromo-4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanediamide;

9-[[azetidin-1-yl(oxo)acetyl](methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(+)-9-[(azetidin-1-ylsulfonyl)(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-N-(2-{[(3-chloro-4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanediamide;

(+)-N-(4-fluoro-3-methylbenzyl)-3-hydroxy-9-[methyl(morpholin-4-ylsulfonyl)amino]-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-9-[[[(dimethylamino)sulfonyl]acetyl](methyl)amino]-N-(4-fluoro-3-methylbenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(4-methylpiperazin-1-yl)sulfonyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(+)-N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(4-methylpiperazin-1-yl)sulfonyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(4-methylpiperazin-1-yl)sulfonyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-(7S)-7-amino-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

(-)-N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

(+)-N-(2-[[ (4-fluorobenzyl)amino]carbonyl]-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

N-(2-[[ (4-fluoro-3-methylbenzyl)amino]carbonyl]-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

N-(2-[[ (3-chloro-4-methylbenzyl)amino]carbonyl]-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

(+)-N-(2-[[ (4-fluoro-3-methylbenzyl)amino]carbonyl]-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

(-)-N-(2-[[ (4-fluoro-3-methylbenzyl)amino]carbonyl]-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

N-(2-[[ (4-fluorobenzyl)amino]carbonyl]-3-hydroxy-8,8-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanediamide;

N-(4-fluorobenzyl)-3-hydroxy-9-[methyl([1,2,4]triazolo[1,5-a]pyrimidin-2-ylcarbonyl)amino]-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-[[ (dimethylamino)sulfonyl](methyl)amino]-N-{4-fluoro-2-[(methylamino)carbonyl]benzyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-{[2-(dimethylamino)-2-oxoethyl]thio}-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-[[ (dimethylamino)carbonyl](methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-[[2-(dimethylamino)-2-oxoethyl]sulfonyl]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(1-oxidopyridin-2-yl)carbonyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

methyl (2-[[[(4-fluorobenzyl)amino]carbonyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)methylcarbamate

N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(morpholin-4-ylsulfonyl)acetyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(cyclopropylmethyl)-N-(2-[[[(4-fluorobenzyl)amino]carbonyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N',N'-dimethylethanediamide;

9-[[2-[(dimethylamino)sulfonyl]-2-methylpropanoyl](methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-[[[(dimethylamino)sulfonyl]acetyl](methyl)amino]-3-hydroxy-4-oxo-N-(quinolin-8-ylmethyl)-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(3-hydroxy-2-[[[(3-methylbenzyl)amino]carbonyl]-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanediamide;

N-(2-[[[(3,4-difluorobenzyl)amino]carbonyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanediamide;

N-(2-[[[(4-fluorobenzyl)amino]carbonyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N',N'-dimethyl-N-(pyridin-2-ylmethyl)ethanediamide;

9-[(dimethylaminocarbonylmethyl)[(dimethylamino)sulfonyl]amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9[(4-morpholinylcarbonylmethyl)(dimethylamino)sulfonyl]amino}-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(+)-N-(2-{{(4-fluoro-3-methylbenzyl)amino}carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanedi-  
amide;

N-(2-{{(3-chloro-4-fluorobenzyl)amino}carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanedi-  
amide;

(-) N-(2-{{(4-chlorobenzyl)amino}carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanedi-  
amide;

(-)-(7S)-7-[acetyl(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

8-(dimethylamino)-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

8-[acetyl(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-10-morpholin-4-yl-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepine-2-carboxamide;

10-[[[(dimethylamino)sulfonyl](methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-10-[methyl(methylsulfonyl)amino]-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-10-{methyl[(methylsulfonyl)acetyl]amino}-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-10-(6-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl)-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-10-{methyl[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepine-2-carboxamide; and

8-[[[(dimethylamino)sulfonyl](methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-2-carboxamide.

11. (original) A compound according to claim 10, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

(-)-N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(methylsulfonyl)acetyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanediamide;

N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanediamide;

N-(2-{[(3-chlorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanediamide;

N-(4-fluorobenzyl)-3-hydroxy-9-(6-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl)-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanediamide;

(+)-N-(4-fluorobenzyl)-3-hydroxy-9-(6-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl)-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-{methyl(pyrrolidin-1-ylsulfonyl)amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

9-[(azetidin-1-ylsulfonyl)(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-N-(4-fluorobenzyl)-3-hydroxy-9-[methyl(morpholin-4-ylsulfonyl)amino]-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(+)-N-(4-fluorobenzyl)-3-hydroxy-9-[methyl(morpholin-4-ylsulfonyl)amino]-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(+)-9-[(azetidin-1-ylsulfonyl)(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-9-[[[(dimethylamino)sulfonyl]acetyl](methyl)amino]-N-(4-fluoro-3-methylbenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(-)-N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(4-methylpiperazin-1-yl)sulfonyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

(+)-N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(4-methylpiperazin-1-yl)sulfonyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(4-methylpiperazin-1-yl)sulfonyl]amino}-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

N-(2-[[[(4-fluorobenzyl)amino]carbonyl]-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

(-)-N-(2-[[[(4-fluorobenzyl)amino]carbonyl]-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

(+)-N-(2-[[[(4-fluorobenzyl)amino]carbonyl]-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

N-(2-[[[(4-fluoro-3-methylbenzyl)amino]carbonyl]-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

(+)-N-(2-[[[(4-fluoro-3-methylbenzyl)amino]carbonyl]-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide;

(-)-N-(2-[[[(4-fluoro-3-methylbenzyl)amino]carbonyl]-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N',N'-trimethylethanediamide; and

N-(2-[[[(4-fluorobenzyl)amino]carbonyl]-3-hydroxy-8,8-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-N,N',N'-trimethylethanediamide.

12. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, ~~any one of claims 1 to 11~~, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

13. (currently amended) A combination useful for treating or preventing infection by HIV, or for preventing, treating or delaying the onset of AIDS, which is a therapeutically effective amount of a compound according to claim 1, ~~any one of claims 1 to 11~~, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors.

14. (currently amended) ~~Use of a compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, A method~~ for inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

15. (canceled)

16. (currently amended) ~~Use of a compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, A method~~ for preventing or treating infection by HIV or for preventing, treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

17. (canceled)